IRIS PubliCatt

Pugliese, Daniela
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.741
EU - Europa 1.507
AS - Asia 550
AF - Africa 14
Continente sconosciuto - Info sul continente non disponibili 2
SA - Sud America 1
Totale 3.815
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.723
DE - Germania 461
SE - Svezia 349
SG - Singapore 219
IT - Italia 195
CN - Cina 179
IE - Irlanda 112
FR - Francia 95
UA - Ucraina 88
GB - Regno Unito 73
ID - Indonesia 72
IN - India 36
RU - Federazione Russa 36
FI - Finlandia 30
CA - Canada 17
PL - Polonia 16
BE - Belgio 13
TR - Turchia 12
IR - Iran 11
KR - Corea 11
CI - Costa d'Avorio 10
NL - Olanda 10
CZ - Repubblica Ceca 7
ES - Italia 6
AT - Austria 4
JP - Giappone 4
BG - Bulgaria 3
LT - Lituania 3
A2 - ???statistics.table.value.countryCode.A2??? 2
HU - Ungheria 2
AR - Argentina 1
CH - Svizzera 1
GR - Grecia 1
HK - Hong Kong 1
IL - Israele 1
KZ - Kazakistan 1
MA - Marocco 1
MD - Moldavia 1
MX - Messico 1
NG - Nigeria 1
PH - Filippine 1
PT - Portogallo 1
SC - Seychelles 1
TN - Tunisia 1
TW - Taiwan 1
VN - Vietnam 1
Totale 3.815
Salva come PNG Salva come JPEG
Città #
Chandler 451
Ashburn 180
Singapore 177
Dublin 109
New York 93
Jacksonville 77
Jakarta 71
San Mateo 61
Dearborn 54
Ann Arbor 44
Cattolica 43
Milan 36
Boston 34
Princeton 34
Beijing 30
Nürnberg 30
Wilmington 30
Moscow 29
Nanjing 29
Marseille 27
Munich 27
Los Angeles 25
Rome 25
Bremen 23
Houston 23
Boardman 17
Lawrence 17
Fairfield 15
Redwood City 14
Brussels 13
Lancaster 13
Seattle 12
Shenyang 12
Warsaw 12
Izmir 11
Seoul 11
Abidjan 10
Leawood 10
Nanchang 10
Woodbridge 10
Augusta 9
Detroit 9
Toronto 9
Washington 8
Cagliari 7
Jiaxing 7
London 7
Norwalk 7
Brno 6
Hebei 6
Lappeenranta 6
Mountain View 6
Paris 6
Pune 6
Sacramento 6
Andover 5
Hefei 5
Helsinki 5
Tianjin 5
Ardabil 4
Cambridge 4
Edinburgh 4
Guasila 4
Kish 4
San Diego 4
Vienna 4
Atlanta 3
Changchun 3
Changsha 3
Chelsea 3
Costa Mesa 3
Fremont 3
Madrid 3
Miami 3
Millbury 3
Ottawa 3
San Jose 3
Shanghai 3
Sofia 3
University Park 3
Wuhan 3
A Coruña 2
Amsterdam 2
Ancona 2
Busto Arsizio 2
Cento 2
Collegeville 2
Florence 2
Frankfurt am Main 2
Jinan 2
Kashan 2
Kraków 2
Kunming 2
Lille 2
Monmouth Junction 2
Montreal 2
Mumbai 2
Napoli 2
Pavia 2
Portocannone 2
Totale 2.185
Salva come PNG Salva come JPEG
Nome #
FOXP3⁺ T regulatory cell modifications in inflammatory bowel disease patients treated with anti-TNFα agents 153
Comparison of Quantiferon-TB Gold versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease patients. 144
Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study 144
Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn's disease: an open-label pilot study 139
Immune response to influenza A/H1N1 vaccine in inflammatory bowel disease patients treated with anti TNF-α agents: Effects of combined therapy with immunosuppressants. 135
Infliximab in Steroid-dependent Ulcerative Colitis: Effectiveness and Predictors of Clinical and Endoscopic Remission. 135
Achievement of sustained deep remission with adalimumab in a patient with both refractory ulcerative colitis and seronegative erosive rheumatoid arthritis 120
Prevalence and natural history of hepatitis B and C infections in a large population of IBD patients treated with anti-tumor necrosis factor-α agents 114
Ileal Crohn's disease: CEUS determination of activity 105
Anti-TNF alpha in the treatment of ulcerative colitis: a valid approach for organ-sparing or an expensive option to delay surgery? 103
Magnesium Absorption in Intestinal Cells: Evidence of Cross-Talk between EGF and TRPM6 and Novel Implications for Cetuximab Therapy 98
Therapeutic drug monitoring of anti-TNF-α agents in inflammatory bowel diseases 87
Benefit–risk assessment of golimumab in the treatment of refractory ulcerative colitis 84
Management of perianal fistulas in Crohn's disease: an up-to-date review 76
What is the best way to manage screening for infections and vaccination of inflammatory bowel disease patients? 76
Therapeutic drug monitoring is more cost-effective than a clinically-based approach in the management of loss of response to infliximab in inflammatory bowel disease: an observational multi-centre study. 71
Challenges in crohn’s disease management after gastrointestinal cancer diagnosis 68
Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease 66
Adalimumab in active ulcerative colitis: a "real-life" observational study 65
Comment on: Emergence of severe spondyloarthropathy-related entheseal pathology following successful vedolizumab therapy for inflammatory bowel disease 65
Clinical management of rheumatologic conditions co-occurring with inflammatory bowel diseases 65
Comparison of performances of infliximab biosimilars CT-P13 versus SB2 in the treatment of inflammatory bowel diseases: a real-life multicenter, observational study in Italy 64
Frontiers in drug research and development for inflammatory bowel disease 60
Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease 59
Combination therapy in inflammatory bowel disease – from traditional immunosuppressors towards the new paradigm of dual targeted therapy 59
TRPM7 Is Overexpressed in Human IBD-Related and Sporadic Colorectal Cancer and Correlates with Tumor Grade 58
Transition of inflammatory bowel disease patients from pediatric to adult care: an observational study on a joint-visits approach 56
Impact of SARS-CoV-2 Infection on the Course of Inflammatory Bowel Disease in Patients Treated with Biological Therapeutic Agents: A Case-Control Study. 54
Drug-Related Pneumonitis in Patients Receiving Vedolizumab Therapy for Inflammatory Bowel Disease 53
Impact of COVID-19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: Reorganisational response in a high-volume Italian inflammatory bowel disease centre 53
Management of difficult-to-treat patients with ulcerative colitis: focus on adalimumab 51
Changes in admissions, and hospitalization outcomes of IBD patients in an Italian tertiary referral center over a 13-year period 51
Severe eosinophilic asthma and aspirin-exacerbated respiratory disease associated to eosinophilic gastroenteritis treated with mepolizumab: A case report 51
Anti TNF-α therapy for ulcerative colitis: current status and prospects for the future 49
Therapeutic drug monitoring with vedolizumab in inflammatory bowel disease 49
Dual Targeted Therapy: a possible option for the management of refractory Inflammatory Bowel Disease 48
Combination therapy in inflammatory bowel disease – from traditional immunosuppressors towards the new paradigm of dual targeted therapy 48
Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: An IG-IBD study 46
Orphan patients with inflammatory bowel disease - when we treat beyond evidence 44
Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches 41
Switching from IFX originator to biosimilar CT-P13 does not impact effectiveness,safety and immunogenicity in a large cohort of IBD patients 41
Letter: SARS-CoV-2 infection in two IBD patients treated with dual targeted therapy 40
The PROSit cohort of infliximab biosimilar in IBD: A prolonged follow-up on the effectiveness and safety across Italy 39
Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS-CoV-2 infection: an IG-IBD study 39
Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches 39
Predictors and early markers of response to biological therapies in inflammatory bowel diseases 38
Reply to managing patients with ulcerative colitis with infliximab in primary and referral gastroenterology centers 37
Switching from IFX originator to biosimilar CT-P13 does not impact effectiveness,safety and immunogenicity in a large cohort of IBD patients 37
Comparison of Performances of Adalimumab Biosimilars SB5, ABP501, GP2017, and MSB11022 in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study 36
Sustained clinical efficacy and mucosal healing of thiopurine maintenance treatment in ulcerative colitis: A real-life study 36
Diet and nutrients in gastrointestinal chronic diseases 35
Radiomics could predict surgery at 10 years in Crohn's disease 33
Long-term safety of in utero exposure to anti-TNFα drugs for the treatment of inflammatory bowel disease: Results from the multicenter European TEDDY study 33
The thrilling journey of sars-cov-2 into the intestine: From pathogenesis to future clinical implications 32
Targeting IL12/23 in ulcerative colitis: update on the role of ustekinumab 31
Real-world efficacy and safety of vedolizumab in managing ulcerative colitis versus Crohn's disease: results from an Italian multicenter study 28
Morbidly Obese Patient With Ulcerative Colitis Treated With Endoscopic Gastroplasty: A Case Report 24
Transition from intravenous to subcutaneous biological therapies in inflammatory bowel disease: An online survey of patients 22
The educational role of IBD nurses in Italy in vaccinations: do not miss the moment for COVID-19 21
Patient-Reported Outcomes for the Assessment of Sexual Health Among Patients Affected by Inflammatory Bowel Disease 20
Serial Fecal Microbiota Infusions via Colonoscopy for Active Ulcerative Colitis: A Feasibility, Safety, and Translational Monocentric Italian Study 19
Ustekinumab safety and effectiveness in patients with ulcerative colitis: results from a large real-life study 18
Cellular and Molecular Determinants of Biologic Drugs Resistance and Therapeutic Failure in Inflammatory Bowel Disease 17
Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: the IG‐IBD LIVE study 14
SARS-CoV-2 infection in patients with inflammatory bowel disease: comparison between the first and second pandemic waves 14
Predictors of Efficacy of Janus Kinase Inhibitors in Patients Affected by Ulcerative Colitis 12
Replacement of Adalimumab Originator to Adalimumab Biosimilar for a Non-Medical Reason in Patients with Inflammatory Bowel Disease: A Real-life Comparison of Adalimumab Biosimilars Currently Available in Italy 12
Use of tofacitinib as first or second-line therapy is associated with better outcomes in patients with ulcerative colitis: data from a real-world study 11
Switching from VEDOlizumab intravenous to subcutaneous formulation in ulcerative colitis patients in clinical remission: The SVEDO Study, an IG-IBD study 9
Effectiveness and Safety of Switching from Intravenous to Subcutaneous Vedolizumab Formulation in Inflammatory Bowel Disease Patients in Clinical Remission 9
Challenges in Crohn's Disease Management after Gastrointestinal Cancer Diagnosis 6
Totale 3.909
Salva come PNG Salva come JPEG
Categoria #
all - tutte 19.420
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 19.420
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020261 0 0 0 0 28 54 28 20 28 10 58 35
2020/2021252 13 20 5 28 31 14 16 10 32 10 62 11
2021/2022458 37 19 8 70 8 10 10 65 9 25 90 107
2022/20231.127 148 147 78 182 71 130 54 103 143 15 36 20
2023/2024767 18 161 30 72 23 126 45 48 41 39 72 92
2024/2025329 20 43 137 30 99 0 0 0 0 0 0 0
Totale 3.909